Last updated: March 24, 2025
Sponsor: Vanderbilt-Ingram Cancer Center
Overall Status: Active - Recruiting
Phase
N/A
Condition
Lymphoproliferative Disorders
Mycosis Fungoides
Treatment
Quality-of-Life Assessment
Objective Grading of Skin Findings
Clinical Study ID
NCT02702310
VICC RAD 1633
P30CA068485
NCI-2015-02293
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Biopsy confirmed mycosis fungoides stage IB-IIIA
Skin manifestations of mycosis fungoides that are refractory to or have relapsed onat least one prior therapy, which may include topical steroids
Life expectancy > 6 months
Exclusion
Exclusion Criteria:
Serious medical condition that would make treatment unsafe
Pregnant or lactating patient
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Quality-of-Life Assessment
Phase:
Study Start date:
May 22, 2016
Estimated Completion Date:
September 30, 2026
Study Description
Connect with a study center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee 37232
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.